Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Skin and Mucosal Delivery (Focus Group – SMD)

Ex vivo platform using viable human skin to investigate subcutaneous administration of macromolecules

Yogeshvar N. KALIA – Full professor, University of Geneva

    Poster Presenter(s)

  • Si Gou, PhD

    Scientific collaboratrice
    University of Geneva
    Geneva, Switzerland, Geneve, Switzerland

Introduction: Subcutaneous (SC) injection is the principal method for the administration of monoclonal antibodies, peptides, and vaccines, as well as hyaluronic acid (HA)-based formulations. We recently reported an ex vivo "full thickness" human skin model containing hypodermis that retained viability for up to 9 days and which was used to observe the “bio-stimulating effects” of subcutaneously injected HA products on ECM production1

Learning Objectives:

  • Identify key biomarkers.
  • Optimize workflow to process human skin specimen for bioanalysis.
  • Establish an ex vivo platform base on the viable human skin explants combined with multiple bioanalytical method.